Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02114268 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 342
- Enrollment target
NCT02114268 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 342 participants.
The verdict
NCT02114268, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 342 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the safety, tolerability and pharmacokinetics of an extended half-life anti-respiratory syncytial virus (RSV) monoclonal antibody compared to placebo when administered to healthy adult participants.
Interventions
- DRUG Placebo
- DRUG MEDI8897 Intravenous
- DRUG MEDI8897 Intramuscular
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 342 participants |
| Start Date | 2014-04 |
| Est. Completion | 2015-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02114268
The ClinicalTrials.gov registry entry for NCT02114268 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 342 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02114268 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02114268 about?
NCT02114268 is a clinical study titled "A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults". The purpose of this study was to evaluate the safety, tolerability and pharmacokinetics of an extended half-life anti-respiratory syncytial virus (RSV) monoclonal antibody compared to placebo when administered to healthy adult participants.
What is the current status of trial NCT02114268?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 342 participants. The study started on 2014-04. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02114268?
The interventions under investigation include: Placebo (DRUG), MEDI8897 Intravenous (DRUG), MEDI8897 Intramuscular (DRUG).
Who is sponsoring clinical trial NCT02114268?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.